HeiLongJiang ZBD Pharmaceutical Co Ltd

The company maintains a debt-to-equity ratio of 0.5, indicating a relatively balanced capital structure. Its enterprise value to revenue ratio of 13.22 suggests a moderate valuation relative to its revenue. However, the company's liquidity is assessed as medium, and its net cash position is negative after subtracting total debt, signaling potential liquidity constraints. In terms of profitability, the company's operating cash flow of 322,095,200 CNY reflects its ability to generate cash from operations. However, without access to industry-specific preferred metrics or cohort medians, a direct comparison to industry benchmarks is not possible at this time. The company's revenue concentration is not disclosed in the available data, and no specific geographic or segment breakdown is provided. This limits the ability to assess exposure to particular markets or product lines. The company's growth trajectory is not explicitly outlined in the available data. No numeric deltas or forward-looking revenue projections are provided to assess future performance. The company's risk profile includes a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, indicating potential challenges in meeting short-term obligations. No adjustments to valuations have been applied, and no dilution sources are disclosed in the available data. No recent events, such as filings or transcripts, are provided in the available data to inform the company's current strategic or operational developments.